Scout | Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01

This opportunity is no longer accepting applications.

grant

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)

This funding opportunity supports the development of genome editing therapies for Alzheimer's-related dementias (ADRD). It focuses on improving promising therapeutic leads, preparing them for further studies needed before clinical trials. The goal is to optimize candidates with proven effectiveness, ability to be manufactured, distributed in the body, and effectively engage targets. The grant …

Source

Agency: National Institutes of Health

Sub-agency: National Institute of Neurological Disorders and Stroke

Program: SBIR

Award

Award Ceiling: $1M

Funding Amount: $1M

Dates

Opportunity Released: August 13, 2024

Open for Submission: August 13, 2024

Submission Deadline: November 19, 2024

Application Window Closes: November 19, 2024

Keywords

genome editing

therapeutic leads

Alzheimer's Disease-Related Dementias

IND-enabling studies

proof-of-concept studies

bioactivity

biodistribution

in vivo efficacy

clinical application

Frontotemporal dementia

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers